{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:30:45Z","timestamp":1793302245126,"version":"4.5.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T00:00:00Z","timestamp":1630108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,1,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>The efficacy of romosozumab for severe osteoporosis is uncertain in patients with osteogenesis imperfecta (OI). This report introduced a severe osteoporotic case of OI to examine the effect of romosozumab on bone fragility. A 64-year-old man with OI was referred to our department for finding out the cause of his repeated fractures. He was medicated with alendronate for only 1 year, 8 years ago, but it did not prevent repeated fractures, and thus, he had not received any treatments for osteoporosis since then. However, recently, the frequency of fractures had increased. At presentation, his lumbar and bilateral total hip bone mineral density (BMD) values were severely decreased to 0.546 and 0.209\u2009g\/cm2, respectively. Because of his severe osteoporosis, we started romosozumab treatment with eldecalcitol. Romosozumab (210\u2009mg) was injected subcutaneously every month. At 12\u2009months after drug initiation, his lumbar and total hip BMD increased by 22.0% and 136.4% versus pre-treatment levels, respectively. Bone formation markers increased, and bone resorption markers decreased at 12\u2009months of the therapy. Neither hypocalcaemia nor any other severe adverse effects were observed in this severe osteoporotic case. This study revealed good responses of BMD and bone turnover markers to romosozumab treatment, which can be considered as an effective treatment option for osteoporotic OI patients.<\/jats:p>","DOI":"10.1093\/mrcr\/rxab018","type":"journal-article","created":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T11:12:33Z","timestamp":1630149153000},"page":"128-133","source":"Crossref","is-referenced-by-count":25,"title":["Efficacy of romosozumab for osteoporosis in a patient with osteogenesis imperfecta: A case report"],"prefix":"10.1093","volume":"6","author":[{"given":"Masashi","family":"Uehara","sequence":"first","affiliation":[{"name":"Department of Orthopaedic Surgery, Shinshu University School of Medicine, Matsumoto, Nagano, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5612-4382","authenticated-orcid":false,"given":"Yukio","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Shinshu University School of Medicine, Matsumoto, Nagano, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Nakano","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Shinshu University School of Medicine, Matsumoto, Nagano, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Miyazaki","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Shinshu University School of Medicine, Matsumoto, Nagano, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takako","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Shinshu University School of Medicine, Matsumoto, Nagano, Japan"},{"name":"Department of Human Nutrition, Faculty of Human Nutrition, Tokyo Kasei Gakuin University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Shinshu University School of Medicine, Matsumoto, Nagano, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,8,28]]},"reference":[{"key":"2022011123194948000_R1","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/S0140-6736(04)16051-0","article-title":"Osteogenesis imperfecta","volume":"363","author":"Rauch","year":"2004","journal-title":"Lancet"},{"key":"2022011123194948000_R2","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/jmg.16.2.101","article-title":"Genetic heterogeneity in osteogenesis imperfecta","volume":"16","author":"Sillence","year":"1979","journal-title":"J Med Genet"},{"key":"2022011123194948000_R3","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/ajmg.a.36545","article-title":"Osteogenesis imperfecta: clinical diagnosis, nomenclature and severity assessment","volume":"164A","author":"Van Dijk","year":"2014","journal-title":"Am J Med Genet A"},{"key":"2022011123194948000_R4","doi-asserted-by":"crossref","DOI":"10.1007\/s11657-015-0222-7","article-title":"Swedish osteoporosis care","volume":"10","author":"Jonsson","year":"2015","journal-title":"Arch Osteoporos"},{"key":"2022011123194948000_R5","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJM199810013391402","article-title":"Cyclic administration of pamidronate in children with severe osteogenesis imperfecta","volume":"339","author":"Glorieux","year":"1998","journal-title":"N Engl J Med"},{"key":"2022011123194948000_R6","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1159\/000331128","article-title":"Reshaping of vertebrae during treatment with neridronate or pamidronate in children with osteogenesis imperfecta","volume":"76","author":"Semler","year":"2011","journal-title":"Horm Res Paediatr"},{"key":"2022011123194948000_R7","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.bone.2006.10.010","article-title":"Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment","volume":"40","author":"Land","year":"2007","journal-title":"Bone"},{"key":"2022011123194948000_R8","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N Engl J Med"},{"key":"2022011123194948000_R9","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"},{"key":"2022011123194948000_R10","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1080\/14712598.2017.1280455","article-title":"Romosozumab for the treatment of osteoporosis","volume":"17","author":"Bandeira","year":"2017","journal-title":"Expert Opin Biol Ther"},{"key":"2022011123194948000_R11","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"},{"key":"2022011123194948000_R12","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.cell.2006.08.039","article-title":"CRTAP is required for prolyl 3-hydroxylation and mutations cause recessive osteogenesis imperfecta","volume":"127","author":"Morello","year":"2006","journal-title":"Cell"},{"key":"2022011123194948000_R13","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1056\/NEJMoa063804","article-title":"Deficiency of cartilage-associated protein in recessive lethal osteogenesis imperfecta","volume":"355","author":"Barnes","year":"2006","journal-title":"N Engl J Med"},{"key":"2022011123194948000_R14","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/S0140-6736(15)00728-X","article-title":"Osteogenesis imperfecta","volume":"387","author":"Forlino","year":"2016","journal-title":"Lancet"},{"key":"2022011123194948000_R15","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/humu.20429","article-title":"Consortium for osteogenesis imperfecta mutations in the helical domain of type I collagen: regions rich in lethal mutations align with collagen binding sites for integrins and proteoglycans","volume":"28","author":"Marini","year":"2007","journal-title":"Hum Mutat"},{"key":"2022011123194948000_R16","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/S0140-6736(13)61091-0","article-title":"Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial","volume":"382","author":"Bishop","year":"2013","journal-title":"Lancet"},{"key":"2022011123194948000_R17","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s00223-013-9770-2","article-title":"Teriparatide treatment in adult patients with osteogenesis imperfecta type I","volume":"93","author":"Gatti","year":"2013","journal-title":"Calcif Tissue Int"},{"key":"2022011123194948000_R18","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1172\/JCI71101","article-title":"Evaluation of teriparatide treatment in adults with osteogenesis imperfecta","volume":"124","author":"Orwoll","year":"2014","journal-title":"J Clin Invest"},{"key":"2022011123194948000_R19","doi-asserted-by":"crossref","first-page":"10890","DOI":"10.1074\/jbc.M807994200","article-title":"Characterization of the structural features and interactions of sclerostin: molecular insight into a key regulator of Wnt-mediated bone formation","volume":"284","author":"Veverka","year":"2009","journal-title":"J Biol Chem"},{"key":"2022011123194948000_R20","doi-asserted-by":"crossref","first-page":"356","DOI":"10.5435\/00124635-200806000-00008","article-title":"Osteogensis imperfecta: diagnosis and treatment","volume":"16","author":"Burnei","year":"2008","journal-title":"J Am Acad Othop Surg"},{"key":"2022011123194948000_R21","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.ocl.2013.06.010","article-title":"Advances in the orthopedic management of osteogenesis imperfecta","volume":"44","author":"Laron","year":"2013","journal-title":"Orhop Clin North Am"},{"key":"2022011123194948000_R22","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1359\/JBMR.041232","article-title":"Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study","volume":"20","author":"Gatti","year":"2005","journal-title":"J Bone Miner Res"},{"key":"2022011123194948000_R23","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/jbmr.3452","article-title":"Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: a randomized, double-blind, phase 2, parallel group study","volume":"33","author":"McClung","year":"2018","journal-title":"J Bone Miner Res"},{"key":"2022011123194948000_R24","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/jbmr.3312","article-title":"Serum sclerostin levels in adults with osteogenesis imperfecta: comparison with normal individuals and response to teriparatide therapy","volume":"33","author":"Nicol","year":"2018","journal-title":"J Bone Miner Res"}],"container-title":["Modern Rheumatology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mrcr\/advance-article-pdf\/doi\/10.1093\/mrcr\/rxab018\/41818857\/rxab018.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/6\/1\/128\/42106798\/rxab018.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/6\/1\/128\/42106798\/rxab018.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T02:47:01Z","timestamp":1642560421000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mrcr\/article\/6\/1\/128-133\/6359044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,28]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,8,28]]},"published-print":{"date-parts":[[2022,1,7]]}},"URL":"https:\/\/doi.org\/10.1093\/mrcr\/rxab018","relation":{},"ISSN":["2472-5625"],"issn-type":[{"value":"2472-5625","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,1,1]]},"published":{"date-parts":[[2021,8,28]]}}}